Summary of CRISPR Therapeutics Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Event**: Virtual Oncology Leadership Summit - **Date**: February 18, 2026 Key Points Industry Focus - CRISPR Therapeutics is engaged in multiple disease areas, with a strong focus on oncology, cardiovascular diseases, autoimmune diseases, and Type 1 diabetes [3][4] Oncology Programs - **ZugoCell (formerly CTX112)**: A next-generation allogeneic CAR-T therapy targeting CD19, designed to improve potency and safety compared to earlier generations [4][5] - **Allogeneic CAR-T**: Made from healthy donor-derived cells, with advanced edits to enhance efficacy and safety, aiming for autologous-like performance [5][6] Key Edits in ZugoCell - **Beta-2M Knockout**: Prevents immune system from recognizing allogeneic cells as foreign, enhancing persistence [8][9] - **RGNASE1 Knockout**: Retains a naive T cell phenotype, allowing for better expansion and reduced exhaustion [10][11] - **TGF-beta Receptor 2 Knockout**: Prevents exhaustion of CAR-T cells, enhancing potency [10][11] Clinical Strategy - **Autoimmune Diseases**: Rapidly enrolling patients for indications like lupus, myositis, and scleroderma, with plans to expand further [17][18] - **Oncology**: Aiming for high complete response (CR) rates and durability, with initial CR rates for ZugoCell reaching nearly 70% [20][21] Regulatory Pathway - Parallel development in oncology and autoimmune indications, with discussions with regulators expected to guide future trials [27][28] Pricing Strategy - Targeting a price point of around $200K for allogeneic CAR-T therapies, significantly lower than current autologous therapies priced at $350K-$400K [52][53] In Vivo CAR-T Development - Developing both transient and permanent CAR-T therapies using LNP-mediated delivery, with a focus on safety and efficacy [54][55] - Permanent CARs could potentially eliminate tumors with a single injection, offering a significant advancement in oncology [56][57] Market Opportunities - Significant potential in both U.S. and international markets, particularly in regions where autologous therapies are not feasible due to cost and availability [48][49] Future Directions - Continued focus on data collection and analysis in both oncology and autoimmune spaces, with a strong emphasis on achieving long-term remissions and safety [31][32][39] Conclusion - CRISPR Therapeutics is positioned to make significant advancements in both oncology and autoimmune therapies through innovative CAR-T technologies, with a clear strategy for regulatory approval and market entry.

Core Insights - Cellectis S.A. (CLLS) is a biotech company focused on developing allogeneic CAR-T therapies using its proprietary Transcription Activator-Like Effector Nucleases (TALEN) technology and PulseAgile electroporation [1] Company Overview - Cellectis targets high-unmet medical needs and heavily pretreated patients suffering from B-cell malignancies [1]